Form 4: Verona Pharma CFO Gifts 1.2M Ordinary Shares

Verona Pharma's Chief Financial Officer, Mark W. Hahn, reported gifting 1,200,000 Ordinary Shares on August 29, 2025.

Summary

• Mark W. Hahn, Chief Financial Officer of Verona Pharma plc, reported a disposition of 1,200,000 Ordinary Shares.
• The transaction occurred on August 29, 2025, and was classified as a gift (transaction code 'G') with a price of $0.
• Following this transaction, Mr. Hahn directly beneficially owns 11,264,968 Ordinary Shares.
• This beneficial ownership includes 2,375,000 Ordinary Shares underlying Restricted Share Units (representing 296,875 ADSs) and 8,889,968 Ordinary Shares underlying 1,111,246 ADSs.
• Each American Depositary Share (ADS) represents eight (8) Ordinary Shares of Verona Pharma plc.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction (gift of shares) by the CFO, which is a neutral event in terms of company performance or strategic direction. It does not indicate any positive or negative operational developments.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note a reduction in the Chief Financial Officer's direct ownership, though the transaction was a gift rather than a sale for cash, and significant beneficial ownership remains.

Key Dates

Recommendation

The filing details a routine insider transaction where the CFO gifted a portion of his shares. This event, in isolation, does not provide sufficient new information regarding the company's financial health, operational performance, or strategic direction to warrant a change in investment recommendation. Investors should maintain their current position based on broader company fundamentals and market conditions.

Keywords

Verona Pharma, VRNA, Mark W. Hahn, CFO, Insider Transaction, Form 4, Share Gift, Beneficial Ownership, Ordinary Shares, ADSs, Restricted Share Units